CN113302206A - 治疗脂质代谢失调的方法 - Google Patents

治疗脂质代谢失调的方法 Download PDF

Info

Publication number
CN113302206A
CN113302206A CN201980089105.XA CN201980089105A CN113302206A CN 113302206 A CN113302206 A CN 113302206A CN 201980089105 A CN201980089105 A CN 201980089105A CN 113302206 A CN113302206 A CN 113302206A
Authority
CN
China
Prior art keywords
antibody
trem2
mammal
trem
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980089105.XA
Other languages
English (en)
Chinese (zh)
Inventor
G·阿斯塔里塔
G·迪保罗
林凯琳
K·M·门罗
A·A·纽金特
B·范伦格里奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denali Therapeutics Inc
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of CN113302206A publication Critical patent/CN113302206A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980089105.XA 2018-11-26 2019-11-26 治疗脂质代谢失调的方法 Pending CN113302206A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862771456P 2018-11-26 2018-11-26
US62/771,456 2018-11-26
US201962817955P 2019-03-13 2019-03-13
US62/817,955 2019-03-13
US201962890506P 2019-08-22 2019-08-22
US62/890,506 2019-08-22
PCT/US2019/063427 WO2020112889A2 (en) 2018-11-26 2019-11-26 Methods for treating dysregulated lipid metabolism

Publications (1)

Publication Number Publication Date
CN113302206A true CN113302206A (zh) 2021-08-24

Family

ID=68988303

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980089105.XA Pending CN113302206A (zh) 2018-11-26 2019-11-26 治疗脂质代谢失调的方法

Country Status (7)

Country Link
US (1) US20230132366A9 (https=)
EP (1) EP3887401A2 (https=)
JP (1) JP7607559B2 (https=)
CN (1) CN113302206A (https=)
CA (1) CA3120970A1 (https=)
MA (1) MA54296A (https=)
WO (1) WO2020112889A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117771226A (zh) * 2023-12-28 2024-03-29 山东博森医学工程技术有限公司 一种加快骨关节炎损伤修复的促进剂

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110506055A (zh) 2017-02-17 2019-11-26 戴纳立制药公司 工程改造的转铁蛋白受体结合多肽
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020117715A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
BR112021015656A2 (pt) 2019-02-20 2021-10-05 Denali Therapeutics Inc. Anticorpos anti-trem2 e métodos de uso dos mesmos
JP2023512450A (ja) 2020-01-13 2023-03-27 デナリ セラピューティクス インコーポレイテッド 抗ｔｒｅｍ２抗体及びその使用方法
WO2021146256A1 (en) 2020-01-13 2021-07-22 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
CA3178900A1 (en) * 2020-06-11 2021-12-16 Marc MARTINEZ-LLORDELLA Trem2 chimeric receptor
JP2023536916A (ja) * 2020-08-05 2023-08-30 ビジル・ニューロサイエンス・インコーポレイテッド Ｔｒｅｍ２アゴニストを使用した、コロニー刺激因子１受容体機能不全に関連する疾患の治療
CN115015412B (zh) * 2022-05-26 2024-07-05 江苏独步生物科技有限公司 一种与中枢神经损伤修复相关的分子靶标及其应用
WO2025046298A2 (en) 2023-09-01 2025-03-06 iTeos Belgium SA Anti-trem2 antibodies and methods of use
WO2025064933A1 (en) * 2023-09-22 2025-03-27 The Trustees Of Columbia University In The City Of New York Restoring tim4 in liver macrophages to treat non-alcoholic steatohepatitis (nash)
WO2025194147A1 (en) * 2024-03-15 2025-09-18 The Children's Medical Center Corporation Therapeutic modulation of trem2 and uses thereof in retinal degeneration
CN118983095A (zh) * 2024-08-01 2024-11-19 中国人民解放军总医院第五医学中心 脂质在hiv感染者抗逆转录病毒治疗后免疫重建结果预测中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005128010A (ja) * 2003-10-03 2005-05-19 Takeda Chem Ind Ltd インスリン抵抗性改善剤のスクリーニング方法
CN102307899A (zh) * 2009-01-28 2012-01-04 特拉维夫医学中心医学研究,基础设施及健康服务基金 炎症、自身免疫疾病和心血管疾病的嗜酸细胞活化趋化因子-2(ccl24)抑制剂
CN108738323A (zh) * 2015-10-06 2018-11-02 艾利妥 抗trem2抗体及其使用方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR14523E (fr) 1911-02-06 1911-12-30 Daniel German Caswell Perfectionnements dans les vélocipèdes
US4326055A (en) 1977-12-22 1982-04-20 Hoffmann-La Roche Inc. Stilbene derivatives
DE3202100A1 (de) 1982-01-23 1983-08-04 Basf Ag, 6700 Ludwigshafen Substituierte benzoesaeure-4-hydroxyanilide, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JP4001618B2 (ja) 1991-12-18 2007-10-31 ザ ソールク インスチチュート フォア バイオロジカル スタディズ レチノイド受容体によって仲介される過程の修飾方法およびそれに有用な化合物
ATE195716T1 (de) 1992-04-22 2000-09-15 Ligand Pharm Inc Retinoid-x rezeptor selektive verbindungen
US5780676A (en) 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US5466861A (en) 1992-11-25 1995-11-14 Sri International Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
ES2129115T3 (es) 1993-01-11 1999-06-01 Ligand Pharm Inc Compuestos que tienen actividad selectiva para los receptores de retinoides x, y medios para la modulacion de procesos mediados por receptores de retinoides x.
JPH08505852A (ja) 1993-01-11 1996-06-25 リガンド・ファーマシューティカルズ・インコーポレーテッド レチノイドｘレセプターに対する選択性を有する化合物
US5399586A (en) 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
JPH08512197A (ja) 1993-04-07 1996-12-24 リガンド・ファーマシューティカルズ・インコーポレーテッド 受容体アゴニストのスクリーニング方法
PL180048B1 (en) 1994-08-10 2000-12-29 Fhoffmann La Roche Ag Ligands of retinic acid x-receptors
CN1121374C (zh) 1994-12-30 2003-09-17 配位体药物股份有限公司 新的三烯类视黄酸化合物及方法
US5721103A (en) 1994-12-30 1998-02-24 Ligand Pharmaceuticals Incorporated Trienoic retinoid compounds and methods
JPH09330101A (ja) 1996-06-13 1997-12-22 Kokusai Chodendo Sangyo Gijutsu Kenkyu Center 制御装置及び方法
IT1286031B1 (it) 1996-10-24 1998-07-07 Enichem Spa Procedimento per la produzione di polimeri vinilaromatici ad elevato grado di sindiotassia
US6969711B2 (en) 1997-05-26 2005-11-29 Kowa Company, Ltd. Cyclic diamine compounds and medicine containing the same
US6316503B1 (en) 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
WO2001041704A2 (en) 1999-12-13 2001-06-14 Merck & Co., Inc. Method for the prevention and/or treatment of atherosclerosis
US20030086923A1 (en) 1999-12-13 2003-05-08 Sparrow Carl P. Method for the prevention and/or treatment of atherosclerosis
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
CA2471311A1 (en) 2001-12-21 2003-07-24 Pharmacia Corporation Aromatic thioether liver x-receptor modulators
EP1465869B1 (en) 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulators of lxr
US20050123580A1 (en) 2002-02-28 2005-06-09 Burris Thomas P. Method of treating atherosclerosis and hypercholesterolemia
MXPA04011690A (es) 2002-05-24 2005-03-31 Pharmacia Corp Moduladores de receptor x de higado de sulfona.
WO2003099769A1 (en) 2002-05-24 2003-12-04 Pharmacia Corporation Anilino liver x-receptor modulators
AU2003272552A1 (en) 2002-09-17 2004-04-08 Pharmacia Corporation Aromatic liver x-receptor modulators
WO2004058175A2 (en) 2002-12-23 2004-07-15 Irm Llc Novel use of liver x receptor agonists
US20050009837A1 (en) 2003-05-20 2005-01-13 City Of Hope Modulators of lipid metabolism and methods of use
AU2004298486A1 (en) 2003-12-12 2005-06-30 Wyeth Quinolines useful in treating cardiovascular disease
EP1773781A2 (en) 2004-08-03 2007-04-18 Wyeth Indazoles useful in treating cardiovascular diseases
CA2662965A1 (en) 2006-09-19 2008-03-27 Wyeth Use of lxr agonists for the treatment of osteoarthritis
US9149492B2 (en) 2008-10-08 2015-10-06 Trustees Of Dartmouth College Method for selectively inhibiting ACAT1 in the treatment of alzheimer's disease
JP5719340B2 (ja) 2009-03-20 2015-05-20 レティーナ インプラント アーゲー 能動型網膜インプラント
WO2013056232A2 (en) 2011-10-13 2013-04-18 Case Western Reserve University Rxr agonists compounds and methods
WO2013090616A1 (en) 2011-12-13 2013-06-20 Io Therapeutics, Inc. Autoimmune disorder treatment using rxr agonists
WO2015038585A1 (en) 2013-09-11 2015-03-19 Trustees Of Dartmouth College Method for selectively inhibiting acat1 in the treatment of alzheimer's disease
WO2015061686A2 (en) 2013-10-25 2015-04-30 St. Jude Children's Research Hospital, Inc. Retinoid x receptor-gamma agonists and retinoid x receptor-alpha antagonists for treatment of cancer
US10100308B2 (en) 2014-05-29 2018-10-16 Trustees Of Dartmouth College Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases
CA2955086A1 (en) 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
EP3318257B1 (en) 2015-06-30 2021-07-28 National University Corporation Okayama University Drug for preventing or treating inflammatory bowel disease
WO2017058866A1 (en) 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
EP3368160B1 (en) 2015-10-31 2023-05-17 IO Therapeutics, Inc. Treatment of nervous system disorders using thyroid hormone neutral doses of rxr agonists
EP3570883A2 (en) * 2017-01-17 2019-11-27 Yeda Research and Development Co. Ltd Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
DK3601358T5 (da) 2017-08-03 2024-09-02 Alector Llc Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
AU2018383709B2 (en) 2017-12-12 2025-09-11 Pionyr Immunotherapeutics, Inc. Anti-TREM2 antibodies and related methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005128010A (ja) * 2003-10-03 2005-05-19 Takeda Chem Ind Ltd インスリン抵抗性改善剤のスクリーニング方法
CN102307899A (zh) * 2009-01-28 2012-01-04 特拉维夫医学中心医学研究,基础设施及健康服务基金 炎症、自身免疫疾病和心血管疾病的嗜酸细胞活化趋化因子-2(ccl24)抑制剂
CN108738323A (zh) * 2015-10-06 2018-11-02 艾利妥 抗trem2抗体及其使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MIN PARK等: "Triggering receptor expressed on myeloid cells 2 (TREM2) promotes adipogenesis and diet-induced obesity", 《DIABETES 》, vol. 64, no. 1, pages 117 - 127, XP055671908, DOI: 10.2337/db13-1869 *
秦涛: "TREM-1、TREM-2在非酒精性脂肪性肝炎时肝组织表达的研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》, no. 09, pages 1 - 40 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117771226A (zh) * 2023-12-28 2024-03-29 山东博森医学工程技术有限公司 一种加快骨关节炎损伤修复的促进剂

Also Published As

Publication number Publication date
JP2022513114A (ja) 2022-02-07
WO2020112889A9 (en) 2021-06-10
MA54296A (fr) 2021-10-06
US20230132366A9 (en) 2023-04-27
US20220025039A1 (en) 2022-01-27
CA3120970A1 (en) 2020-06-04
JP7607559B2 (ja) 2024-12-27
WO2020112889A3 (en) 2020-07-30
EP3887401A2 (en) 2021-10-06
WO2020112889A2 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
JP7607559B2 (ja) 脂質代謝調節不全の治療方法
AU2021208482B2 (en) Anti-TREM2 antibodies and methods of use thereof
JP7842822B2 (ja) 抗ｔｒｅｍ２抗体及びその使用方法
US20210238256A1 (en) Fusion protein
JP7094698B2 (ja) 抗体、使用、及び方法
KR102831784B1 (ko) 클로토 단백질 수준을 평가하고 증가시키기 위한 산물 및 방법
TWI890727B (zh) 抗trem2 抗體及其使用方法
JP7167027B2 (ja) 抗ｐｃｓｋ９抗体およびその使用
US20160046722A1 (en) Novel medicaments comprising an antibody composition enriched with predominant charge isoform
US11028184B2 (en) Long-acting PCSK9-specific binding protein and application thereof
WO2025181485A1 (en) P75 neurotrophin receptor-fc fusion protein for use in pain therapy
US20250353901A1 (en) Fusion proteins against sialosylated glycosphingolipids and sialated glycoproteins and uses thereof
EP4482869A1 (en) Il-6 inhibitor as treatment for nephropathy
HK40063035A (en) Anti-trem2 antibodies and methods of use thereof
EA049305B1 (ru) Антитела к trem2 и способы их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination